학술논문
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Document Type
Article
Author
Domchek, S.M.; Postel-Vinay, S.; Im, S.-A.; Park, Y.H.; Delord, J.-P.; Italiano, A.; Alexandre, J.; You, B.; Bastian, S.; Krebs, M.G.; Wang, D.; Waqar, S.N.; Lanasa, M.; Rhee, J.; Lai, Z.; Opincar, L.; Herbolsheimer, P.; Gao, H.; Rocher-Ros, V.; Jones, E.V.; Gulati, S.; Coenen-Stass, A.; Kozarewa, I.; Angell, H.K.; Kaufman, B.
Source
In: The Lancet Oncology . (The Lancet Oncology, September 2020, 21(9):1155-1164)
Subject
Language
English
ISSN
14745488
14702045
14702045